Drug Profile

VYN 202

Alternative Names: TAY-B2; VYN-202

Latest Information Update: 07 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator In4Derm
Developer VYNE Therapeutics
Class Anti-inflammatories; Antifibrotics; Antipsoriatics; Antirheumatics; Small molecules
Mechanism of Action Bromodomain and extraterminal domain protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

02 Jul 2025 The US FDA lifts a clinical hold on a phase Ib trial in Plaque psoriasis (PO)
02 Jul 2025 Adverse events, efficacy and pharmacodynamics data from a phase Ib trial in Plaque psoriasis released by VYNE Therapeutics
02 Jul 2025 VYNE Therapeutics stops enrolment in a phase Ib trial in Plaque psoriasis (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com